Cantargia ABCHIX:CANTAS 37 EV-to-FCF is 3.04 as of Jun. 30, 2026, which is 22% below its 10-year median of 3.91. GuruFocus rates CHIX:CANTAS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 331 Biotechnology companies, Cantargia AB ranks better than 69.18% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cantargia AB's Enterprise Value is kr479.5 Mil.
Cantargia AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr157.6 Mil. Therefore, Cantargia AB's EV-to-FCF for today is 3.04.
The historical rank and industry rank for Cantargia AB's EV-to-FCF or its related term are showing as below:
CHIX:CANTAs'
s EV-to-FCF Range Over the Past 10 Years
Min: 1.44 Med: 3.91 Max: 8.42
Current: 3.01
During the past 13 years, the highest EV-to-FCF of Cantargia AB was 8.42. The lowest was 1.44. And the median was 3.91.
CHIX:CANTAs's EV-to-FCF is ranked better than 69.18% of 331
companies
in the Biotechnology industry
Industry Median: 15.57
vs CHIX:CANTAs: 3.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cantargia AB's PE Ratio (TTM) for today is calculated as:
Cantargia AB's share price for today is kr4.174.
Cantargia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.650.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cantargia AB EV-to-FCF Related Terms
Cantargia AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Cantargia AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CANTAS vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Cantargia AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantargia AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cantargia AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cantargia AB's EV-to-FCF falls into.
Cantargia AB's current Enterprise Value is kr479.5 Mil.
Cantargia AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr157.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantargia AB (CHIX:CANTAS) has a EV-to-FCF of 3.04 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cantargia AB and its competitors. This is 22% below median its historical median of 3.91. Over the past decade, Cantargia AB's EV-to-FCF has ranged from 1.44 to 8.42. According to the industry distribution chart, Cantargia AB ranks #102 out of 331 companies in the Biotechnology industry, placing it in the top 30.8%.
Is Cantargia AB's EV-to-FCF too high?
Cantargia AB's current EV-to-FCF of 3.04 is 22% below median its 10-year median of 3.91. Over the past 10 years, this metric has ranged from a low of 1.44 to a high of 8.42. The Biotechnology industry median EV-to-FCF is 15.57. Cantargia AB's value of 3.04 is 80.5% below this industry median. Based on the distribution chart, Cantargia AB ranks #102 out of 331 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cantargia AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cantargia AB ranks #102 out of 331 companies for EV-to-FCF. This puts Cantargia AB in the upper half of its industry. The industry median EV-to-FCF is 15.57. Cantargia AB's value of 3.04 is 80.5% below this benchmark. Historically, Cantargia AB's own EV-to-FCF has ranged from 1.44 to 8.42 over the past decade. While the company's 10-year median is 3.91 vs. the industry median of 15.57, Cantargia AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cantargia AB's current EV-to-FCF of 3.04 is 80.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cantargia AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantargia AB's current EV-to-FCF is 3.04, which is 22% below median its own 10-year median of 3.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current EV-to-FCF of 3.04. The current EV-to-FCF is 3.04, which is 22% below median its 10-year median of 3.91 and 80.5% below the Biotechnology industry median of 15.57. Cantargia AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current EV-to-FCF is 3.04 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score
Get the complete analysis for CHIX:CANTAS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CANTAS has been successfully added to your 
